Clinical Study

Sex, Prescribing Practices and Guideline Recommended, Blood Pressure, and LDL Cholesterol Targets at Baseline in the BARI 2D Trial

Michelle F. Magee,1 Jacqueline E. Tamis-Holland,2 Jiang Lu,3 Vera A. Bittner,4 Maria Mori Brooks,3 Neusa Lopes,5 Alice K. Jacobs,6 and BARI 2D Study Group3

1MedStar Health Research Institute at Washington Hospital Center and Georgetown University School of Medicine, MedStar Diabetes Institute, 100 Irving Street NW, No. 4114, Washington, DC 20010, USA
2Mount Sinai Saint Luke’s Hospital, New York, NY 10025, USA
3University of Pittsburgh, Pittsburgh, PA 15261, USA
4University of Alabama at Birmingham, Birmingham, AL 35294, USA
5Heart Institute (InCor), 01238-000 São Paulo, SP, Brazil
6Boston University Medical Center, Boston, MA 02118, USA

Correspondence should be addressed to Michelle F. Magee; michelle.f.magee@medstar.net

Received 11 April 2014; Accepted 15 October 2014

Academic Editor: Giuseppina T. Russo

1. Background

Control of blood glucose, blood pressure (BP), and low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes (DM) and cardiovascular disease (CVD) is key to achieve optimal outcomes [1]. Nationally, attainment of CVD prevention goals for patients with diabetes is suboptimal [2–6] and appears to be worse in women than in men [6–21]. This may be partially explained by a more adverse CVD risk profile in women and/or by differences in therapies given to women compared with men [6, 8, 11, 13, 15, 16, 22–25]. It is often difficult to determine how the dosing of these medications or the class of agents prescribed impact the differences in response to therapies that are seen by sex. Furthermore, less is known regarding whether there are also sex differences in response to drugs used for secondary CVD risk reduction. At present, there are no sex-based differences in guideline treatment recommendations for these three risk factors.

The bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial was designed to evaluate outcomes in a cohort of patients with type 2 diabetes and known angiographically documented coronary artery disease (CAD), defined as one or more significant lesions deemed suitable for elective revascularization [26]. The BARI 2D baseline data
set affords an opportunity to compare clinical characteristics and pharmacotherapeutic prescribing practices in a large cohort of middle-aged men and women with diabetes and CVD recruited 2001–2005. This paper compares the attainment of guideline recommended HbA1c, BP, and LDL-C benchmarks at study entry by sex and the relationship between number, type, and doses of drugs that were prescribed in women and men at study entry. We hypothesized that the approach to drug therapy would be similar in women and men who were enrolled in BARI 2D, and as such benchmark targets for HbA1c, BP, and LDL-C would also be similar by sex after adjusting for the number of relevant drugs prescribed.

2. Methods

BARI 2D (ClinicalTrials.gov Identifier: NCT00006305) is a multicenter, randomized NIH-funded trial designed to determine optimal treatment strategies for patients with DM and documented CAD suitable for elective revascularization. A detailed description of the study design and patient population has been previously reported [26]. Approval was obtained both from the University of Pittsburgh and from individual site institutional committees on human research. Subjects were recruited, consented, and randomized from 49 clinical sites in USA, Canada, Brazil, Mexico, the Czech Republic, and Austria between January 2001 and March 2005. Eligibility criteria included a diagnosis of DM and angiographically documented CAD not requiring immediate revascularization.

At the time of randomization, demographics, clinical history, physical exam, test results, and medications were collected. HbA1c and lipids were measured in a BARI 2D core laboratory and secondarily at point of care for clinical management decisions. Only those patients with quality baseline information were included in the present analysis. To classify level of control for study-designated treatment targets, measures of HbA1c, fasting LDL-C, and BP were collected. United States guideline recommendations for treatment goals for diabetes, hypertension, and cholesterol were set at <7% for HbA1c, <100 mg/dL for LDL-C, and ≤130/80 mm Hg for BP during the BARI 2D recruitment years [27] until 2004 when the LDL-C goal was tightened to allow consideration of <70 mg/dL [28]. Core laboratory derived HbA1c and LDL-C were available in 95% and 92% of patients, respectively. Missing core lab values were augmented by clinical site measures.

Therapeutic agents were categorized into antianginal/antihypertensive, antplatelet/anticoagulant, antihyperlipidemic, and antidiabetes agents. Antidiabetes drugs were further subdivided into insulin providing (IP), insulin sensitizing (IS), and IP-IS neutral [29]. Each drug and its total daily dose at study entry were recorded. Diabetes agent and statin doses were further stratified to designate their being either within or above recommended starting dose(s) as stated in FDA approved prescribing information as of September 2007. The latter analysis was not performed for BP lowering drugs as these medications were not solely prescribed for BP control and we were not able to ascertain the indication(s) for which each BP agent was prescribed.

Statistical comparisons of proportions and means were made between sexes for demographic variables, clinical history, lab measures, and use of pharmacotherapeutic agents. For lipid lowering and oral diabetes agents, the proportion of patients whose clinical measures were at target was also compared by sex according to dose stratification. Chi-square tests and t-tests were performed as appropriate; P values less than 0.05 were considered statistically significant. In order to test sex differences in achieving treatment goals, outcomes of multiple logistic regression models for the defined targets of HbA1c and LDL-C BP were evaluated. Odds ratios of achieving treatment targets for women and men were calculated using logistic models adjusted for age, race ethnicity, education, physical activity, current cigarette smoking status, BMI, duration of diabetes, history of CAD prior to enrollment, hypertension, and number of relevant medications. All analyses were performed using SAS version 9.1.3 (Cary, NC).

3. Results

Among the 2368 patients enrolled, 2321 subjects had quality data and were included in the analysis. Among this group, there were 686 women (mean age 62.9 years, 44.5% non-white) and 1635 men (mean age 62.2 years; 30.2% nonwhite). Demographic and clinical history characteristics are shown in Table 1. Women entering BARI 2D had a heavier burden of CVD risk factors than men, including higher BMI, longer duration of diabetes, higher prevalence of hypertension, a more sedentary lifestyle, and worse self-related health. Women less often had a history of cigarette smoking and were less likely than men to have had prior MI or CABG. Women had higher HbA1c and LDL-C levels and higher average BP than men.

Table 2 depicts the pharmacotherapeutic agents that were prescribed for women and men just prior to study entry. A similar percentage by sex was treated with most categories of agents, although significantly fewer women were taking metformin and sulfonylureas. Insulin and diuretics were being taken by more women than men. A similar number of women and men were taking some form of antplatelet/anticoagulant; however, fewer women than men were taking aspirin.

The average number of drugs prescribed for each category of risk was determined. Within the category of antidiabetes agents, the number of drugs being taken did not differ between women and men (1.54 ± 0.81 versus 1.58 ± 0.88, P = 0.30). However, women were taking more antihypertensive drugs (2.36 ± 1.05 versus 2.17 ± 1.01, P < 0.001) and fewer lipid lowering drugs (0.84 ± 0.53 versus 0.91 ± 0.58, P = 0.004) than men. The average number of drugs being taken for the 4 risk categories assessed, including antplatelet/anticoagulants, approached 7 agents and did not differ between women and men (6.64 ± 2.08 versus 6.57 ± 2.17, P = 0.43).

The average drug dose and the percentage of patients on titrated doses for statins and antidiabetes agents are shown in
Table 1: BARI 2D demographics and clinical history by sex.

| Demographic/clinical history                      | Female (N = 686) | Male (N = 1635) | P value |
|--------------------------------------------------|------------------|-----------------|---------|
| Age at entry (years), mean ± SD                  | 62.9 ± 9.3       | 62.2 ± 8.7      | 0.08    |
| Race ethnicity                                   |                  |                 | <0.001  |
| White, non-Hispanic                              | 55.5%            | 69.8%           |         |
| Black or African-American, non-Hispanic          | 27.7%            | 12.4%           |         |
| Hispanic                                         | 13.0%            | 12.5%           |         |
| Asian and others                                 | 3.8%             | 5.3%            |         |
| Region and country                               |                  |                 | <0.001  |
| United States and Canada                         | 74.9%            | 79.1%           |         |
| México and Brazil                                | 22.1%            | 17.7%           |         |
| Czech Republic & Austria                         | 3.1%             | 3.3%            |         |
| Education level                                  |                  |                 | <0.001  |
| < High school                                    | 46.1%            | 33.0%           |         |
| ≥ High school                                    | 53.9%            | 67.0%           |         |
| BMI (kg/m²), mean ± SD                           | 32.9 ± 6.9       | 31.3 ± 5.4      | <0.001  |
| Diabetes duration (years), mean ± SD             | 12.2 ± 9.6       | 9.7 ± 8.1       | <0.001  |
| History of hypertension                          | 87.2%            | 80.4%           | <0.001  |
| History of hypercholesterolemia                  | 82.9%            | 81.4%           | 0.4     |
| History of MI                                    | 27.9%            | 33.6%           | 0.007   |
| History of CHF                                   | 7.8%             | 6.0%            | 0.1     |
| CABG prior to randomization                      | 4.5%             | 7.2%            | 0.02    |
| PCI prior to randomization                       | 20.1%            | 19.4%           | 0.7     |
| Cerebrovascular Accident                         | 11.0%            | 9.3%            | 0.2     |
| Physical Activity                                |                  |                 | <0.001  |
| Sedentary                                        | 28.2%            | 19.3%           |         |
| Mild to moderate                                  | 69.6%            | 77.4%           |         |
| Strenuous                                         | 2.2%             | 3.3%            |         |
| Cigarette smoking                                |                  |                 | <0.001  |
| Never smoked                                     | 51.9%            | 25.4%           |         |
| Current smoker                                   | 9.8%             | 13.4%           |         |
| Self-rated health                                |                  |                 | <0.001  |
| Excellent to good                                | 46.8%            | 56.4%           |         |
| Fair to poor                                     | 53.3%            | 43.6%           |         |
| Mean HbA1C (%)                                   | 8.0 ± 1.7        | 7.5 ± 1.6       | <0.001  |
| Mean blood pressure (mm Hg)                      |                  |                 |         |
| Systolic (mm Hg)                                 | 134.8 ± 22.6     | 130.4 ± 18.7    | <0.001  |
| Diastolic (mm Hg)                                | 73.8 ± 12.5      | 74.9 ± 10.6     | 0.04    |
| Mean LDL cholesterol (mg/dL)                     | 102.9 ± 34.8     | 93.5 ± 32.2     | <0.001  |

MI = myocardial infarction; CHF = congestive heart failure.

Table 3. Women were taking higher average doses of atorvastatin and pravastatin than men. For each antidiabetes drug, average doses did not differ and the percentages on titrated doses were similar by sex, except for the percentage on >0.4 units/kg/day of insulin which was being taken by more women. There were no significant differences in the percent of women and men taking statin dose above the recommended starting dose(s) per FDA approved prescribing information.

An analysis by sex of the percent of subjects who met the prespecified clinical targets for HbA1c, BP, LDL-C, and BP is detailed in Table 4. Significantly, fewer women were at goal for both HbA1c and LDL-C than men. There was no difference by sex in the percent at target for BP. After adjustment for covariates, including clinical variables as well as number of relevant agents prescribed, the odds of being at target for HbA1c and LDL-C remained significantly lower for women than for men. The odds of being at target for BP remained similar.

4. Discussion

Control of CVD risk factors substantially improves outcome among high-risk patients with DM [1]. Based on this information, clinical guidelines specific to individuals with diabetes that were in effect at the time of BARI 2D recruitment specified benchmark targets for control of HbA1c, LDL-C, and BP. The BARI 2D baseline data analysis allows comparison of physician prescribing practices, intensity of drug therapy prescribed, and degree of attainment of standards of care for HbA1c, LDL-C, and BP in women and men with DM.
| Pharmacotherapeutic agent  | Total \( (N = 2321) \) | Female \( (N = 686) \) | Male \( (N = 1635) \) | \( P \) value |
|-----------------------------|-------------------|-----------------|-----------------|-------------|
| **Antidiabetes agents**     |                   |                 |                 |             |
| Any diabetes drug           | 91.4%             | 92.1%           | 91.1%           | 0.44        |
| Insulin sensitizing         | 60.9%             | 57.7%           | 62.3%           | 0.04        |
| Metformin                   | 54.1%             | 50.2%           | 55.7%           | 0.02        |
| TZD                         | 18.8%             | 16.4%           | 19.8%           | 0.06        |
| Insulin Providing           | 75.6%             | 77.8%           | 74.7%           | 0.11        |
| Sulfonylurea                | 53.6%             | 47.7%           | 56.0%           | \(< 0.001\) |
| Meglitinide                 | 0.7%              | 1.0%            | 0.6%            | 0.29        |
| Insulin                     | 27.8%             | 36.3%           | 24.3%           | \(< 0.001\) |
| **Lipid lowering agents**  |                   |                 |                 |             |
| Any lipid drug              | 79.1%             | 77.3%           | 79.9%           | 0.16        |
| Statin                      | 74.7%             | 73.0%           | 75.4%           | 0.22        |
| Fibrate                     | 8.6%              | 6.3%            | 9.6%            | 0.01        |
| Niacin                      | 2.2%              | 1.5%            | 2.4%            | 0.14        |
| **Blood pressure agents**  |                   |                 |                 |             |
| Any blood pressure drug     | 95.8%             | 95.8%           | 95.8%           | 1.00        |
| ACE or ARB                  | 77.1%             | 75.6%           | 77.7%           | 0.27        |
| Beta-blocker                | 72.9%             | 74.3%           | 73.2%           | 0.32        |
| Calcium channel blocker     | 31.4%             | 33.9%           | 30.4%           | 0.10        |
| Diuretic                    | 38.7%             | 49.9%           | 34.0%           | \(< 0.001\) |
| **Antiplatelet/anticoagulants** |         |                 |                 |             |
| Any antiplatelet/anticoagulant | 91.9%      | 90.5%           | 92.5%           | 0.10        |
| Aspirin                     | 88.0%             | 85.7%           | 89.0%           | 0.03        |
| Ticlopidine/clopidogrel     | 18.0%             | 18.8%           | 17.6%           | 0.49        |

ACE = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker.

| Agent                        | Female | Male | Female | Male | \( P \) value | Threshold | % on titrated dose |
|------------------------------|--------|------|--------|------|--------------|----------|-------------------|
| Taking diabetes drug         | 622    | 1465 | —      | —    | —            | Diabetes drugs | 72% | 73% | 0.63 |
| **Any insulin sensitizing** | 394    | 1015 | —      | —    | —            | IS       | 58% | 62% | 0.27 |
| TZD                          | 111    | 322  | —      | —    | —            | TZD      | 46% | 42% | 0.46 |
| Pioglitazone                 | 61     | 139  | 32.5   | 31.3 | 0.49         | >30 mg   | 36% | 32% | 0.54 |
| Rosiglitazone                | 50     | 183  | 6.7    | 6.0  | 0.12         | >4 mg    | 58% | 50% | 0.30 |
| Metformin                    | 344    | 907  | 1517.5 | 1526.2 | 0.83        | >1000 mg | 58% | 61% | 0.31 |
| **Any insulin providing**   | 515    | 1162 | —      | —    | —            | IP       | 71% | 69% | 0.34 |
| Sulfonylurea                 | 316    | 864  | —      | —    | —            | SU       | 63% | 64% | 0.66 |
| Glyburide                    | 192    | 540  | 18.0   | 13.5 | 0.30         | >5 mg    | 75% | 73% | 0.58 |
| Glipizide                    | 87     | 236  | 17.6   | 14.0 | 0.31         | >10 mg   | 31% | 44% | 0.03 |
| Glimepiride                  | 37     | 88   | 5.1    | 4.3  | 0.17         | >2 mg    | 76% | 66% | 0.28 |
| Insulin                      | 249    | 397  | 0.7 unit/kg | 0.6 unit/kg | 0.17 | >0.4 unit/kg | 75% | 68% | 0.04 |
| **Taking statin**           | 483    | 1186 | —      | —    | —            | Statins  | 46% | 46% | 0.96 |
| Atorvastatin                 | 181    | 443  | 29.4   | 25.0 | 0.01         | >10 mg   | 66% | 62% | 0.36 |
| Lovastatin                   | 16     | 42   | 28.8   | 35.5 | 0.18         | >20 mg   | 38% | 64% | 0.07 |
| Pravastatin                  | 41     | 92   | 32.9   | 24.8 | 0.002        | >40 mg   | 5%  | 1%  | 0.17 |
| Simvastatin                  | 245    | 609  | 28.8   | 29.8 | 0.53         | >20 mg   | 39% | 41% | 0.71 |

IS = insulin sensitizing; IP = insulin providing diabetes drugs; SU = sulfonylurea.
and established CAD across a diversity of physician practice settings. The findings of these baseline data suggest that women enrolled in the BARI 2D trial were as intensively treated with drugs for DM and CVD prevention as men at study entry, with the exception of aspirin which was taken by fewer women than men. Despite equivalence in prescribing practices, women met benchmark targets for HbA1c and LDL-C less often than men. The adjusted odds ratio was in the same direction and of similar magnitude for HbA1c and LDL-C, compared with the unadjusted odds. This demonstrates a robust relationship between sex and achievement of targets. Our findings are consistent with some prior reports that demonstrated that women are less likely than men to achieve control of HbA1c [6, 8, 11, 17, 18] and LDL-C [6–11, 17–21].

A few studies have reported on the likelihood of achieving guideline targets after adjusting for the type of drugs prescribed [11, 12, 30–32]. In the recent report by Rossi et al., of a cohort of Italian diabetes clinic patients, inequalities in attainment of benchmarks were observed with women being more likely than men to have A1C >9.0% in spite of insulin treatment and to have LDL >130 mg/dL in spite of lipid lowering treatment [31], as was the case in the BARID2 cohort. Both the BARID2 and the Italian cohorts demonstrated medical undertreatment of women with aspirin and in the latter undertreatment with ACE-inhibitors was also observed among females. In contrast to these findings, among a Swedish cohort of adults with chest pain referred for a first time diagnostic elective coronary angiography from 2006 to 2008, it was shown that female sex was independently associated with underutilization of guideline recommended therapy. The Swedish data revealed subsequent equivalent use of ACE-inhibitors, beta-blockers, aspirin, and statins among women and men after angiographic diagnosis of obstructive CAD was made [32]. Our detailed analysis of pharmacotherapeutic agents used to control HbA1c, LDL-C, and BP among patients entering the BARID2 study demonstrates that, despite a similar intensity of medications used to control CVD risk factors, women were still less likely to achieve target goals for HbA1c and LDL-C than men. Women enrolled in the BARID2 study had a less favorable risk profile at baseline compared with men, including greater age, longer duration of DM, higher BMI, a higher prevalence of hypertension, a more sedentary lifestyle, and a lower level of education. Although these variables might affect the ability to control HbA1c, LDL-C, and BP, differences were still noted among women and men even after adjustment for these variables, suggesting that alternate factors are likely at play in this sex gap. Various other explanations for the observation that women are less likely than men to reach treatment goals for HbA1c, LDL-C, and BP have been put forward, including biologic factors, medication adherence, and possible differences in the quality of health care delivery by sex.

Women have been shown to receive less aggressive therapies to treat or prevent CVD than men [6, 8, 11, 13, 15, 16, 22–25, 31–33]. In the current report, however, we performed a detailed analysis of number and intensity of medications prescribed for women and men and found very similar dosing of medications used to treat CVD risk factors. If anything, the intensity of therapy was greater in women than men. More women than men were treated with insulin in keeping with their longer duration of diabetes and higher HbA1c levels. Insulin doses (units/kg body weight/day) were also higher in women. The findings that more women than men in BARI 2D were treated with insulin and that women were taking a higher number of units of insulin/kg of body weight daily when compared to men suggest the possibility of a greater degree of insulin resistance among the women. This possibility is also supported by the presence of a higher BMI and a more sedentary lifestyle among the women subjects. Statins were prescribed to a similar percentage of women and men, and a similar number by sex were on a “titrated” dose of statin. The average dose of statins tended to be higher in women. Although fewer women than men were treated with fibrate therapy, the total number of drugs used to treat hypercholesterolemia was similar by sex. On average more total antihypertensive drugs were prescribed to women than men. A similar percentage of women and men were taking an ACE-inhibitor or ARB and/or beta-blockers and more women than men were taking diuretics. The only CVD prevention agent which was prescribed less frequently among BARI2D women was aspirin. Given these findings, we do

| Clinical target                  | % at clinical target | Odds ratio (95% CI)† |
|----------------------------------|----------------------|----------------------|
| HbA1c < 7%                       | 31.9% (N = 686)      | 0.64 (0.53, 0.77)    |
| Blood pressure ≤ 130/80 mm Hg    | 45.0% (N = 1635)     | 0.87 (0.72, 1.04)    |
| LDL < 100 mg/dL                  | 49.8%                | 0.58 (0.48, 0.69)    |
| Achieved all 3 target goals      | 10.9%                | 0.65 (0.49, 0.86)    |

†All clinical targets were adjusted for the following common covariates: sex, age, race ethnicity, education, physical activity, cigarette smoking, duration of diabetes, and BMI. In addition, HbA1c was adjusted for a number of diabetes agents; lipids targets were adjusted for a number of lipids agents and CABG or PCI prior to randomization; blood pressure target was adjusted for a number of antihypertensive agents, CABG or PCI prior to randomization, and history of hypertension. The attainment on all 3 targets was controlled for a number of total drugs, CABG or PCI prior to randomization, and history of hypertension.
not feel that the differences reported were a result of sex differences in prescribing practices.

It is possible that there are inherent biological differences by sex in the response to the pharmacotherapeutic agents used to treat CVD. For example, studies have shown sex differences in the biologic and clinical response to antiplatelet drugs [34, 35], while other studies have suggested differences in the time to achieve adequate control of LDL-C as a function of race and sex [30]. Differences in response to therapies may relate to sex differences in enzymatic activities, glomerular filtration, levels of endogenous hormones, body surface area, and proportion of body fat. It is possible that these biologic differences in women and men impact the efficacy of the drugs used to treat DM, high cholesterol, and hypertension. Previous reports have demonstrated poorer compliance with medications and lifestyle interventions in women than men [7, 20, 36] and an association of adherence to medications and achievement of target goals [7]. Compliance with medications can be influenced by the cost of the medication, the patient’s underlying condition, the frequency of follow-up visits, the use of mail order pharmacies, and sociodemographic variables [20]. Information regarding adherence to therapy prescribed and dietary and lifestyle practices at study entry in BARI 2D was not recorded. We did, however, show that women enrolled in BARI 2D were older than men, had a higher BMI, led more sedentary lifestyles, and had poorer education; all of these factors may directly impact adherence. Our multivariate model attempted to adjust for these variables; however, even after adjustment, sex differences in achievement of goals persisted.

It is also possible that the differences in the outcomes reported by sex relate to higher pretreatment levels of HbA1c, LDL-C, and BP. Some studies have demonstrated that the ability to adequately lower LDL-C is directly correlated with starting LDL-C values [37]. Since we did not have information regarding the “pretreatment” indices for HbA1c, LDL-C, and BP, we cannot determine whether these parameters had any effect on achievement of benchmarks for these targets.

5. Limitations

Baseline data presented in this analysis were obtained by each subject’s self-report. Therefore, information on drugs previously prescribed, their side effects, and information on subject adherence with the prescribed therapy were not available. Each of these variables could potentially impact sex differences in target attainment and limits our ability to determine whether the differential attainment of targets between the sexes is due to adherence factors or actual response to therapy. In addition, the recruitment of subjects from academic medical centers may bias the data, limiting the ability to extrapolate findings to community practices.

6. Conclusions

Women enrolling in BARI 2D were being treated as intensively with diabetes, lipid lowering, and blood pressure drugs as men. Despite equivalence of therapies prescribed, including number of agents prescribed and an apparently equivalent degree of drug dose titration, women less frequently met targets for HbA1c and LDL-C than men. These findings suggest that sex differences in attaining clinical targets cannot be explained solely by sex bias in drug prescribing practices. Other variables such as differences in medication adherence or differences in therapeutic responses to agents used for secondary CVD prevention among women compared to men must be considered. As we strive to decrease the percentage of both women and men with type 2 diabetes who die from CVD, further studies are needed to investigate sex-specific factors that may impact targeted management of risk factors for CVD.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

BARI 2D is funded by the National Heart, Lung and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases (U01 HL061744, U01 HL061746, U01 HL061748, and U01 HL063804). Members of the BARI 2D study group are as follows: (1) University of Pittsburgh, Pittsburgh, PA, (coordinating center); principal investigators: Katherine M. Detre, M.D. and DrPH degrees (deceased) and Sheryl F. Kelsey, Ph.D. degree; coprincipal investigator: Maria Mori Brooks, Ph.D. degree; coinvestigators: Trevor J. Orchard, MBBC, and MMedSci degrees, Stephen B. Thomas, Ph.D. degree, Kim Sutton Tyrrell, RN and DrPH degrees (deceased), and Jamal S. Rana, M.D. and Ph.D. degrees; coordinator: Frani Averbach, M.P.H. and RD degrees; administrative coordinators: Joan M. MacGregor, M.S. degree, Scott M. O’Neal, M.A. degree, Kathleen Pitluga, B.A. degree, Veronica Sansing, Ph.D. degree, Mary Tranchine, B.S. degree, and Sharon W. Crow, M.Ed. degree; statisticians: Marianne (Marnie) Bertolet, Ph.D. degree, Regina Hardison, M.S. degree, Kevin Kip, Ph.D. degree, Manuel Lombardero, M.S. degree, and Jiang Lu, M.S. degree; data managers: Sue Janiszewski, MSIS degree, Darina Protivnak, MSIS degree, and Sarah Reiser, B.S. degree; system programmers: Stephen Barton, ASB degree, Ping Guo, B.S. degree, and Yulia Kushner, B.S. and B.A. degrees; system support: Jeffrey P. Martin, MBA degree, Christopher Kania, B.S. degree, Michael Kania, B.S. degree, and Jeffrey O’Donnell, B.S. degree; consultants: Rae Ann Maxwell, RPh and Ph.D. degrees; Mayo Clinic Foundation, Rochester, MN: study chair: Robert L. Frye, M.D. degree; (3) National Heart, Lung and Blood Institute, Bethesda, MD; (4) National Institutes of Health, Bethesda, MD (program office), project officer: Suzanne Goldberg, RN and MSN degrees; deputy project officer: Yves Rosenberg, M.D. and MPH degrees; NHLBI officers: Patrice Desvigne-Nickens, M.D. degree, Abby Ershow, ScD degree, David Gordon, M.D. and Ph.D. degrees, and Dina Paltoo, Ph.D. and MPH degrees, (5) National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD (cofunding), program Director for diabetes complications:
Teresa L. Z. Jones, M.D. degree, (6) University of São Paulo Heart Institute, São Paulo, Brazil (clinical site): principal investigators: cardiology: Whady Hueb, M.D. degree, José Ramires, M.D. degree, and Neuza Lopes, M.D. degree; diabetes: Bernardo Léo Wajchenberg, M.D. degree; investigators: Eulogio E. Martinez, M.D. degree, Sergio A. Oliveira, M.D. degree, Expedito E. Ribeiro, M.D. degree, and Marcos Perin, M.D. degree; coordinator: Roberto Bettì, M.D. degree, (7) Toronto General Hospital/University Health Network, Toronto, Canada (clinical site): principal investigators: cardiology: Leonard Schwartz, M.D. degree; diabetes: George Steiner, M.D. degree; investigators: Alan Barolet, M.D. degree, and Yolanda Groenewoud, M.D. degree; coordinators: Lisa Mighty, RN CDE degrees, and Kathy Camelon, RD and CDE degrees, (8) Texas Health Science at San Antonio/South Texas Veterans Health Care System, San Antonio, TX (clinical site): principal investigators: cardiology: Robert O’Rourke, M.D. degree (deceased); diabetes: Janet Blodgett, M.D. degree; investigator: Edward Sako, M.D. and Ph.D. degrees; coordinators: Judith Nicastro, RN degree, and Robin Prescott, MSN degree, (9) Mayo Clinic-Rochester Rochester, MN (clinical site, vanguard site): principal investigators: cardiology: Charanjit Rihal, M.D. degree; diabetes: Frank Kennedy, M.D. degree; investigators: Gregory Barness, M.D. degree, Amanda Basu, M.D. degree, Alfredo Clavell, M.D. degree, Robert Frye, M.D. degree, David R. Holmes Jr., M.D. degree, Amir Lerman, M.D. degree, Charles Mullaney, M.D. degree, Guy Reeder, M.D. degree, Robert Rizza, M.D. degree, Hartzell Schaff, M.D. degree, Steven Smith, M.D. degree, Virend Somers, M.D. degree, Thoralf Sundt, M.D. degree, Henry Ting, M.D. degree, and R. Scott Wright, M.D. degree; coordinators: Pam Helgemoe, RN degree, Diane Lesmeister, and Deborah Rolbiecki, LPN degree; (10) Mexican Institute of the Social Security, México City, D.F., México (clinical site): principal investigators: cardiology: Luis Lepe-Montoya, M.D. degree (deceased); diabetesology, Jorge Escobedo, M.D. and CCT degree; coordinators: Rafael Barraza, M.D. degree, Rubén Baleón, M.D. degree, Arturo Campos, M.D. degree, Paula Garcia, M.D. degree, Carlos Lezama, M.D. degree, Carlos Miramontes, M.D. degree, Salvador Ocampo, M.D. degree, Joaquín V. Peñafiel, M.D. degree, Aquiles Valdespino, M.D. degree, Raúl Verdin, M.D. degree, Héctor Albarrán, M.D. degree, Fernando Ayala, M.D. degree, Eduardo Chávez, M.D. degree, and Héctor Murillo, M.D. degree; coordinators: Luisa Virginia Buitrón, M.D. degree, Beatriz Rico-Verdín, M.D. and Ph.D. degrees, and Fabiola Angulo, CCT degree; (11) University Hospitals of Cleveland/CASE Medical School Cleveland, OH (clinical site, vanguard site): principal investigators: cardiology: Dale Adler, M.D. degree, and Austin Arthur Halle, M.D. degree; diabetesology: Faramarz Ismail-Beigi, M.D. and Ph.D. degrees; investigator: Suvinay Paranjape, M.D. degree; coordinators: Stacey Mazzurco, RN degree, and Karen Ridley, RN and BSN degrees; (12) Memphis VA Medical Center/University of Tennessee, Memphis, TN (clinical site): principal investigators: cardiology: Kodangudi Ramanathan, M.D. degree; diabetesology: Solomon Solomon, M.D. degree; nephrology: Barry Wall, M.D. degree; investigator: Darryl Weinman, M.D. degree; coordinators: Tammy Touchstone, RN and BSN degrees, and Lillie Douglas, RN degree; (13) Montréal Heart Institute/Hôtel-Dieu-CHUM Montréal, Canada (clinical site, Vanguard site): principal investigators: cardiology: Martial Bourassa, M.D. degree, and Jean-Claude Tardif, M.D. degree; diabetesology: Jean-Louis Chiasson, M.D. degree, Marc Andre Lavoie, M.D. degree, and Rémi Rabasa-Lhoret, M.D. and Ph.D. degrees; coordinators: Hélène Langelier, BSC and RD degrees, Suzy Foucher, RN and B.A. degrees, and Johanne Trudel, RN and B.S. degrees; (14) Albert Einstein College of Medicine/Montefiore, Bronx, NY (clinical site): principal investigators: cardiology: Scott Monrad, M.D. degree, and Vankeepuram Srinivas, M.D. degree; diabetesology: Joel Zonszein, M.D. degree; investigator: Jill Crandall, M.D. degree; coordinators: Helena Duffy, ANP and CDE degrees, and Eugen Vartolomei, M.D. degree, (15) Fuqua Heart Center/Piedmont Hospital, Atlanta, GA (clinical site): principal investigators: cardiology: William Rogers, M.D. degree; diabetesology: Fernando Ovalle, M.D. degree, and David Bell, MBBC degree; investigators: Vijay K. Misra, M.D. degree (deceased), William B. Hillegass, M.D. degree, and Raed Aql, M.D. degree; coordinators: Penny Pierce, RN and BSN degrees, Melanie Smith, RN and BSN degrees, Leah Saag, RN degree, Ashley Vaughn, RN degree, Dwight Smith, RN degree, Tiffany Grimes, RN degree, Susan Rolli, RN degree, Roberta Hill, RN degree, Beth Dean Barrett, RN degree, Clarinda Morehead, LPN degree, and Ken Doss, (17) Northwestern University Medical School, Chicago, IL (clinical site): principal investigators: cardiology: Charles J. Davidson, M.D. degree; diabetesology: Mark Molitch, M.D. degree; investigator: Niran Beohar, M.D. degree; coordinators: Elaine Massaro, M.S., RN, and CDE degrees, Lynne Goodreau, RN degree, and Fabiola Arroyo, CCE degree, (18) Na Homolce Hospital, Prague, Czech Republic (clinical site): principal investigators: cardiology: Petr Neužil, M.D. and Ph.D. degrees, and Lenka Pavlíčková, M.D. degree; diabetesology: Štěpánka Stehlíková, M.D. degree; Investigator: Jaroslav Benedik, M.D. degree; coordinator: Liz Coling; (19) University of Ottawa Heart Institute/Ottawa Hospital-Riverside Campus, Ottawa, Canada (clinical site): principal investigators: cardiology: Richard Davies, M.D. degree, Christopher Glover, M.D. degree, Michel LeMay, M.D. degree, and Thierry Mesana, M.D. degree; diabetesology: Teik Chye Ooi, M.D. degree, Mark Silverman, M.D. degree, and Alexander Sorisky, M.D. degree; coordinators: Colette Favreau, RN degree, and Susan McClinton, BScN degree, (20) New York Medical College/Westchester Medical Center, Valhalla, NY (clinical site): principal investigators: Cardiology: Melvin Weiss, M.D. degree; diabetesology: Irene Weiss, M.D. degree; investigators: Leo Saille, M.D. degree, and Harichandra Kannam, M.D. degree; coordinators: Joanne C. Kurylas, RN and CDE degrees, and Lorraine Vasi, RN degree,
(21) University, Atlanta, GA (clinical site): principal investigators: cardiology: John Douglas Jr., M.D. degree, Ziyad Ghazzal, M.D. degree, Laurence Sperling, M.D. degree, and Spencer King III, M.D. degree, diabetology: Priya Dayamani, M.D. degree, and Suzanne Gebhart, M.D. degree; investigators: Sabreena Basu, M.D. degree, Tarek Helmy, M.D. degree, and Vin Tangpricha, M.D. and Ph.D. degrees; coordinators: Pamela Hyde, RN degree, Margaret Jenkins, RN, CDE, and CCRC degrees, and Barbara P. Grant, CVT degree, (22) Washington Hospital Center/Georgetown University Medical Center, Washington, DC (clinical site): principal investigators: cardiology: Kenneth Kent, M.D. degree, William Suddath, M.D. degree, and Suzanne Gebhart, M.D. degree; investigators: Sabreena Basu, M.D. degree, Tarek Helmy, M.D. degree, and Vin Tangpricha, M.D. and Ph.D. degrees; coordinators: Pamela Hyde, RN degree, Margaret Jenkins, RN, CDE, and CCRC degrees, and Barbara P. Grant, CVT degree, (23) Quebec Heart Institute/Laval Hospital, Sainte-Foy, Quebec (clinical site): principal investigators: cardiology: Gilles Dagenais, M.D. degree; diabetes: Claude Garceau, M.D. degree; coordinator: Dominique Auger, RN degree, (24) University of British Columbia/Vancouver Hospital, British Columbia, Canada (clinical site): principal investigators: cardiology: Christopher Buller, M.D. degree; diabetes: Tom Elliott, MBBS degree; investigators: Krishnan Ramanathan MBCChB degree, and Donald Ricci, M.D. degree; coordinators: Rebecca Fox, P.A. and M.Sc. degrees, and Daniela Kolesniak, M.D. degree, (25) NYU School of Medicine, New York, NY (clinical site): principal investigators: cardiology: Michael Attubato, M.D. degree, Frederick Feit, M.D. degree, and Stephen Richardson, M.D. degree; investigators: Ivan Pena Sing, M.D. degree, and James Slater, M.D. degree; coordinators: Angela Amendola, M.S., PA-C, RD, and CDE degrees, and Bernardo Vargas, B.S. degree, (26) Lahey Clinic Medical Center, Burlington, MA, (clinical site): principal investigators: cardiology: Nicholas Tsapatsaris, M.D. degree, and Bartholomew Woods, M.D. degree; diabetes: Gary Cushing, M.D. degree; investigators: Martin K. Rutter, M.D. degree, and Premranjan Singh, M.D. degree; coordinators: Gail DesRochers, RN degree, Gail Woodhead, RN degree, Deborah Gannon, M.S. degree, and Nancy Shinopulos Campbell, RN degree, (27) University of Virginia, Charlottesville, VA (clinical site): principal investigators: cardiology: Michael Ragosta, M.D. degree, Ian Sarembock, M.D. degree, and Eric Powers, M.D. degree; diabetes: Eugene Barrett, M.D. degree; coordinators: Linda Jahn, RN and Med degrees, and Karen Murie, RN degree, (28) University of Minnesota/Minnesota Veterans Research Institute, Minneapolis, MN (clinical site): principal investigators: cardiology: Gladwin Das, M.B., B.S., and M.D. degrees, Gardar Sigurdsson, M.D. degree, and Carl White, M.D. degree; diabetes: John Bantle, M.D. degree; investigator: J. Bruce Redmon, M.D. degree; coordinator: Christine Kwong, MPH, RD, and CDE degrees, (29) St. Luke’s/Roosevelt Hospital Center, New York, NY (clinical site): principal investigators: cardiology: Jacqueline Tamis-Holland, M.D. degree; diabetes: Jeanine Albu, M.D. degree; investigators: Judith S. Hochman, M.D. degree, James Slater, M.D. degree, and James Wilentz, M.D. degree; coordinators: Sylvaine Frances, PA, degree, and Deborah Tormey, RN degree, (30) University of Florida, Gainesville, FL (clinical site): principal investigators: cardiology: Carl Pepine, M.D. degree, and Karen Smith, M.D. degree; endocrinology: Laurence Kennedy, MD,FRCP degree; coordinators: Karen Brezner, CCRC degree, and Tempa Curry, RN degree, (31) Saint Louis University, St. Louis, MO (clinical site): principal investigators: cardiology: Frank Bleyer, M.D. degree; diabetes: Stewart Albert, M.D. degree; investigator: Arshag Mooradian, M.D. degree, coordinator: Sharon Plummer, NP degree, (32) University of Texas at Houston, Houston, TX (clinical site): principal investigators: cardiology: Francisco Fuentes, M.D. degree, and Roberto Robles, M.D. degree; diabetes: Victor Lavis, M.D. degree; investigators: Jaime Gomez, M.D. degree, and Cesar Iliescu, M.D. degree; coordinators: Carol Underwood, BSN, RN, and CCRC degrees, Maria Selin Fulton, RN and CDE degrees, Julie Gomez Ramirez, BSN and RN degrees, Jennifer Merta, M.A. degree, and Glenna Scott, RN degree, (33) Kaiser-Permanente Medical Center, San Jose, CA (clinical site): principal investigators: cardiology: Ashok Krishnaswami, M.D. degree; diabetes: Lynn Dowdell, M.D. degree; coordinator: Sarah Berkerheim, RN degree, (34) Henry Ford Heart & Vascular Institute, Detroit, MI (clinical site): principal investigators: endocrinology: Adam Greenbaum, M.D. degree; diabetes: Fred Whitehouse, M.D. degree; coordinators: Raquel Pangilinan, BSN and RN degrees, and Kelly Mann, RN, BSN, and CDE degrees, (35) Boston Medical Center, Boston, MA (clinical site): principal investigators: cardiology: Alice K. Jacobs, M.D. degree; diabetes: Elliot Sterntahl, M.D. degree; investigators: Susana Ebner, M.D. degree, and Zoran Nedeljkovic, M.D. degree; coordinator: Paula Beardsley, LPN degree, (36) Fletcher Allen Health Care (Vanguard site), Burlington, VT (clinical site): principal investigators: cardiology: David Schneider, M.D. degree; diabetes: Richard Prattley, M.D. degree, William Cefalu, M.D. degree, and Joel Schnure, M.D. degree; coordinators: Michaelanne Rowen, RN and CCRC degrees, and Linda Tilton, MS, RD, and DE; (37) Jim Moran Heart & Vascular Institute, Fort Lauderdale, FL (clinical site): principal investigators: cardiology: Alan Niederman, M.D. degree; diabetes: Cristina Mata, M.D. degree; coordinator: Terri Kellerman, RN degree, (38) Baylor College of Medicine, Houston, TX (clinical site): principal investigators: cardiology: John Farmer, M.D. degree; diabetes: Alan J. Garber, M.D. and Ph.D. degrees; investigator: Neal Kleiman, M.D. degree; coordinators: Nancy Howard, RN and BSN degrees, Debra Nichols, RN degree, Madonna Pool, RN and MSN degrees, (39) Duke University, Durham, NC (clinical site): principal investigators: cardiology: Christopher Granger, M.D. degree; diabetes: Mark Feinglos, M.D. degree; investigators: George Adams, M.D. degree, and Jennifer Green, M.D. degree; coordinators: Bernadette Druken, RN and CCRP degrees, and Dani Underwood, MSN and ANP degrees, (40) University of Maryland Hospital, Baltimore, MD (clinical site): principal investigators: cardiology: J. Lawrence Stafford, M.D. degree; diabetes: Thomas Donner, M.D. degree; investigator: Warren Laskey, M.D. degree; coordinator: Dana Beach, RN degree, (41) University of Chicago Medical Center, Chicago, IL (clinical site): principal investigators: cardiology: John Lopez, M.D. degree; diabetes: Andrew Davis, M.D. degree; investigators: David Faxon, M.D. degree, and Sirimon Reutrakul, M.D. degree;
coordinator: Emily Bayer, RN and BSN degrees, (42) University of Pittsburgh Medical Center, Pittsburgh, PA (clinical site): principal investigators: cardiology: Oscar Marroquin, M.D. degree, and Howard Cohen, M.D. degree; diabetology: Mary Korytkowski, M.D. degree; coordinators: Glory Koerbel, MSN and CDE degrees, Lisa Baxendell, RN degree, Debbie Rosenfelder, BSN and CCRC degrees, Louise DeRiso, MSN degree, Carole Farrell, BSN degree, and Tina Vita, RN degree; (43) Washington University/Barnes Jewish Hospital, St. Louis, MO (clinical site): principal investigators: diabetology: Janet McGill, M.D. degree; cardiology: Ronald Krone, M.D. degree, and Richard Bach, M.D. degree; coordinators: Carol Recklein, RN, MHS, and CDE degrees, Kristin M. Luepke, RN and MSN degrees; (44) Mary Jane Clifton, Mount Sinai Medical Center, New York, NY (clinical site): principal investigators: cardiology: Michael E. Farkouh, M.D. and M.Sc. degrees, and Michael C. Kim, M.D. and FACC degrees; diabetology: Donald A. Smith, M.D. and MPH degrees; coordinators: Ida Guzman, RN and ANP degrees, and Arlene Travis, RN and MSN degrees; (45) Mid America Heart Institute, Kansas City, MO (clinical site): principal investigators: cardiology: James O’Keefe, M.D. degree; diabetology: Alan Foraker, M.D. degree, and William Isley, M.D. degree (deceased); investigator: Richard Moe, M.D. and Ph.D. degrees; coordinators: Paul Kennedy, RN degree, Margaret Rosson, LPN degree, and Aimee Long, RN degree; (46) University of Michigan, Ann Arbor, MI (clinical site): principal investigators: cardiology: Eric Bates, M.D. degree; diabetology: William Herman, M.D. and MPH degrees, and Rodica Pop-Busui, M.D. and Ph.D. degrees; investigators: Claire Duvernoy, M.D. degree, and Martin Stevens, MBBCCh degree; coordinators: Ann Luciano, RN degree, and Cheryl Majors, BSN degree, (47) Johns Hopkins Bayview Medical Center, Baltimore, MD (clinical site): principal investigators: cardiology: Sheldon H. Gottlieb, M.D. degree; diabetology: Annabelle Rodriguez, M.D. degree; coordinator: Melanie Herr, RN degree; (48) Brown University/Rhode Island Hospital, Providence, RI (clinical site): principal investigators: cardiology: David Williams, M.D. degree; diabetology: Robert J. Smith, M.D. degree; investigators: J. Dawn Abbott, M.D. degree, and Marc J. Lauflgraben, M.D. degree; coordinators: Mary Grogan, RN degree, and Janice Muratori, RNP degree, (49) Houston VA Medical Center, Houston, TX (clinical site): principal investigators: cardiology: Gabriel Habib, M.D. and M.S. degrees; diabetology: Marco Marcelli, M.D. degree; investigator: Issam Mikati, M.D. degree; coordinators: Emilia Cordero, NP degree, and Gina Caldwell, LVN degree; (50) New York Hospital Queens/Lang Research Center, Queens, NY (clinical site): principal investigators: cardiology: David Schechter, M.D. degree; diabetology: Daniel Lorber, M.D. degree; nephrology: Phyllis August, M.D. and MPH degrees; coordinators: Maisie Brown, RN and MSN degrees, and Patricia Depree, Ph.D., ANP, and CDE degrees; (51) Wilhelminen Hospital, Vienna, Austria (clinical site): principal investigators: cardiology: Kurt Huber, M.D. degree; diabetology: Ursula Hanusch-Enzerer, M.D. degree; investigator: Nelly Jordanova, M.D. degree; coordinators: Dilek Cilesiz, M.D. degree, and Birgit Vogel, M.D. degree; (52) St. Joseph Mercy Hospital/Michigan Heart and Vascular Institute and the Ann Arbor Endocrinology and Diabetes, P.C., Ann Arbor, MI (clinical site): principal investigators: cardiology: Ben McCallister Jr., M.D. degree; diabetology: Michael Kleerekoper, M.D. degree, Kelly Mandagere, M.D. degree, and Robert Urbanic, M.D. degree; investigators: James Bengston, M.D. and MPH degrees, Bobby K. Kong, M.D. degree, Andrew Pruitt, M.D. degree, and Jeffrey Sanfield, M.D. degree; coordinators: Carol Carulli, RN degree, and Ruth Cherly-Strom, MSN degree; (53) The Ohio State University Medical Center, Columbus, OH (clinical site): principal investigators: cardiology: Raymond Magorien, M.D. degree; diabetology: Kwame Osei, M.D. degree; coordinator: Cecilia Casey Boyer, RN, MS, and CDE degrees; (54) Mayo Clinic-Scottsdale, Scottsdale, AZ (clinical site): principal investigators: cardiology: Richard Lee, M.D. degree; diabetology: Pasquale Palumbo, M.D. degree; coordinator: Joyce Wisbey, RN degree, (55) Angiographic Core Laboratory, Stanford University, Stanford, CA: principal investigator: Edwin Alderman, M.D. degree; staff: Fumia Keno, M.D. degree, and Anne Schwarzkopf (deceased); (56) Biochemistry Core Laboratory, University of Minnesota, Minneapolis, MN: principal investigator: Michael Steffes, M.D. and Ph.D. degrees; staff: Maren Nowicki, CLS degree, and Jean Bucksa, CLS degree; (57) ECG Core Laboratory, Saint Louis University, St. Louis, MO (U01 HL061746): principal investigator: Bernard Chaitman, M.D. degree; staff: Jane Eckstein, RN degree, and Karen Stocke, B.S. and MBA degrees, (58) Economics Core Laboratory, Stanford University, Stanford, CA (U01 HL061748): principal investigator: Mark A. Hlatky, M.D. degree; staff: Derek B. Boothroyd, Ph.D. degree, and Kathryn A. Melsop, M.S. degree; (59) Fibrinolyis Core Laboratory, University of Vermont, Burlington, VT (U01 HL063804): principal investigator: Burton E. Sobel, M.D. degree; staff: Michaelanne Rowen, RN and CCRC degrees, and Dagnija Neiman, B.S. degree, (60) Nuclear Cardiology Core Laboratory, University of Alabama at Birmingham, Birmingham, AL (Astellas Pharma US, Inc.): principal investigator: Ami E. Iskandrian, M.D. degree; staff: Mary Beth Schaaf, RN and BSN degrees; (61) Diabetes Management Center, Case Western Reserve University, Cleveland, OH: Director: Saul Genum, M.D. degree; staff: Theresa Bongarni, B.S. degree; (62) Hypertension Management Center, Lahey Clinic Medical Center, Burlington, MA: Codirector: Richard Nesto, M.D. degree; (63) Hypertension Management Center, New York Hospital Queens, Queens, NY: Codirector: Phyllis August, M.D. and MPH degrees; staff: Karen Hultberg, M.S. degree; (64) Lifestyle Intervention Management Center, Johns Hopkins Bayview Medical Center, Baltimore, MD: Codirector: Sheldon H. Gottlieb, M.D. degree; (65) Lifestyle Intervention Management Center, St. Luke’s/Roosevelt Hospital Center, New York, NY: Codirector: Jeanine Albu, M.D. degree; staff: Helene Rosenhouse-Romeo, RD and CDE degrees; (66) Lipid Management Center, University of Pittsburgh, Pittsburgh, PA: Director: Trevor J. Orchard, MBBCCh and MMedSci degrees; staff: Georgia Pambianco, MPH degree, Manuel Lombardero, M.S. degree, (67) Safety Officer, North Canton, OH: Michael Mock, M.D. degree (deceased); Operations Committee: Chair: Robert L. Frye, M.D. degree; members: Maria Mori Brooks, Ph.D. degree, Patrice Desvigne-Nickens, M.D. degree, Abbyershaw, SCd degree, Saul Genum, M.D. degree, Suzanne Goldberg, RN and MSN degrees, David Gordon, M.D. and...
Ph.D. degrees, Regina Hardison, M.S. degree, Teresa L. Z. Jones, M.D. degree, Sheryl Kelsey, Ph.D. degree, Richard Nesto, M.D. degree, Trevor Orchard, MBBCh and MMedSci degrees, Dina Paltoo, Ph.D. and MPH degrees, and Yves Rosenberg, M.D. and MPH degrees; (68) Morbidity and Mortality Classification Committee (MMCC): Chair: Thomas Ryan, M.D. degree; Cochairs: Harold Lebovitz, M.D. degree; members: Robert Brown, M.D. degree, Gottlieb Friesinger, M.D. degree, Edward Horton, M.D. degree, Jay Mason, M.D. degree, Renu Virmani, M.D. degree, and Lawrence Wechsler, M.D. degree; (69) Data and Safety Monitoring Board (DSMB): Chair: C. Noel Bairey-Merz, M.D. degree, former Chair: J. Ward Kennedy, M.D. degree (deceased), Executive Secretary: David Gordon, M.D. and Ph.D. degrees; members: Elliott Antman, M.D. degree, John Colwell, M.D. and Ph.D. degrees, Sarah Fowler, Ph.D. degree, Curt Furberg, M.D. and Ph.D. degrees, Lee Goldman, M.D. degree, Bruce Jennings, MA degree, and Scott Rankin, M.D. degree. BARI 2D received significant supplemental funding from GlaxoSmithKline, Bristol-Myers Squibb Medical Imaging, Inc., Astellas Pharma US, Inc., Merck & Co., Inc, Abbott Laboratories, Inc., and Pfizer, Inc. and generous support from Abbott Laboratories Ltd., MediSense Products, Bayer Diagnostics, Becton, Dickinson and Company, J. R. Carlson Laboratories, Inc., Centocor, Inc., Eli Lilly and Company, LipoScience, Inc., Merck Sante, Novartis Pharmaceuticals Corporation, and Novo Nordisk, Inc.

References

[1] P. Gæde, H. Lund-Andersen, H.-H. Parving, and O. Pedersen, “Effect of a multifactorial intervention on mortality in type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 6, pp. 580–591, 2008.

[2] E. S. Ford, “Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: findings from the National Health and Nutrition Examination Survey 1999–2006,” Journal of Diabetes, vol. 3, no. 4, pp. 337–347, 2011.

[3] J. B. Saaddine, M. M. Engelgau, G. L. Beckles, E. W. Gregg, T. J. Thompson, and K. M. V. Narayan, “A diabetes report card for the United States: quality of care in the 1990s,” Annals of Internal Medicine, vol. 136, no. 8, pp. 565–574, 2002.

[4] H. E. Resnick, G. L. Foster, J. Bardisley, and R. E. Ratner, “Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey,” Diabetes Care, vol. 29, no. 3, pp. 531–537, 2006.

[5] S. H. Saydah, J. Fradkin, and C. C. Cowie, “Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes,” The Journal of the American Medical Association, vol. 291, no. 3, pp. 335–342, 2004.

[6] D. J. Wexler, R. W. Grant, J. B. Meigs, and D. M. Nathan, “Treatment of cardiac risk factors in patients with type 2 diabetes,” Diabetes Care, vol. 28, pp. 514–520, 2005.

[7] E. S. Parris, D. B. Lawrence, L. A. Mohn, and L. B. Long, “Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia,” Diabetes Care, vol. 28, no. 3, pp. 595–599, 2005.

[8] C. E. Bird, A. M. Fremont, A. S. Bierman et al., “Does quality of care for cardiovascular disease and diabetes differ by gender for enrollees in managed care plans?” Women’s Health Issues, vol. 17, no. 3, pp. 131–138, 2007.

[9] A. F. Chou, S. H. Scholle, C. S. Weisman, A. S. Bierman, R. Correa-de-Araujo, and L. Mosca, “Gender disparities in the quality of cardiovascular disease care in private managed care plans,” Women’s Health Issues, vol. 17, no. 3, pp. 120–130, 2007.

[10] S. I. McFarlane, J. Castro, J. Kaur et al., “Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men,” Journal of Clinical Hypertension, vol. 7, no. 2, pp. 73–80, 2005.

[11] I. Gouni-Berthold, H. K. Berthold, C. S. Mantzoros, M. Böhm, and W. Krone, “Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes,” Diabetes Care, vol. 31, no. 7, pp. 1389–1391, 2008.

[12] A. Ferrara, C. M. Mangione, C. Kim et al., “Sex disparities in the control and treatment of modifiable cardiovascular disease risk factors among patients with diabetes,” Diabetes Care, vol. 31, pp. 69–74, 2008.

[13] J. A. Schmittdiel, A. Traylor, C. S. Uratsu, C. M. Mangione, A. Ferrara, and U. Subramanian, “The association of patient-physician gender concordance with cardiovascular disease risk factor control and treatment in diabetes,” Journal of Women’s Health, vol. 18, no. 12, pp. 2065–2070, 2009.

[14] C. J. Homko, L. Zamora, W. P. Santamore, A. Kashem, T. McConnell, and A. A. Bove, “Gender differences in cardiovascular risk factors and risk perception among individuals with diabetes,” Diabetes Educator, vol. 36, no. 3, pp. 483–488, 2010.

[15] A. Kautzky-Willer, M. R. Kamyar, D. Gerhat et al., “Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus,” Gender Medicine, vol. 7, no. 6, pp. 571–583, 2010.

[16] V. G. Vimalananda, D. R. Miller, M. Palnati, C. L. Christiansen, and B. G. Fincke, “Gender disparities in lipid-lowering therapy among veterans with diabetes,” Women’s Health Issues, vol. 21, no. 4, pp. S176–S181, 2011.

[17] M. Šekerić, T. Poljičanin, K. Erjav, A.-M. Liberati-Čizmek, M. Prašek, and Ž. Metelko, “Gender differences in the control of cardiovascular risk factors in patients with type 2 diabetes—a cross-sectional study,” Internal Medicine, vol. 51, no. 2, pp. 161–166, 2012.

[18] L. Franzini, D. Ardigo, F. Cavalot et al., “Women show worse control of type 2 diabetes and cardiovascular disease risk factors than men: results from the MIND.IT Study Group of the Italian Society of Diabetology,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 23, no. 3, pp. 235–241, 2013.

[19] A. F. Chou, L. Wong, C. S. Weisman et al., “Gender disparities in cardiovascular disease care among commercial and medicare managed care plans,” Women’s Health Issues, vol. 17, no. 3, pp. 139–149, 2007.

[20] J. S. Schultz, J. C. O’Donnell, K. L. McDonough, R. Sasane, and J. Meyer, “Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population,” The American Journal of Managed Care, vol. 11, no. 5, pp. 306–312, 2005.

[21] I.-M. Rückert, W. Maier, A. Mielck et al., “Personal attributes that influence the adequate management of hypertension and dyslipidemia in patients with type 2 diabetes. Results from the DIAB-CORE Cooperation,” Cardiovascular Diabetology, vol. 11, article 120, 2012.

[22] A. Ferrara, D. F. Williamson, A. J. Karter, T. J. Thompson, and C. Kim, “Sex differences in quality of health care related to
ischemic heart disease prevention in patients with diabetes: the Translating Research Into Action for Diabetes (TRIAD) study, 2000-2001," *Diabetes Care*, vol. 27, no. 12, pp. 2974–2976, 2004.

[23] H. Tabenkin, C. B. Eaton, M. B. Roberts, D. R. Parker, J. H. McMurray, and J. Borkan, "Differences in cardiovascular disease risk factor management in primary care by sex of physician and patient," *Annals of Family Medicine*, vol. 8, no. 1, pp. 25–32, 2010.

[24] M. E. Larkin, J.-Y. Backlund, P. Cleary et al., "Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC," *Diabetic Medicine*, vol. 27, no. 4, pp. 451–458, 2010.

[25] J. P. Sheppard, S. Singh, K. Fletcher, R. J. McManus, and J. Mant, "Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study," *British Medical Journal*, vol. 345, no. 7866, Article ID e4535, 2012.

[26] M. M. Brooks, R. L. Frye, S. Genuth et al., "Hypotheses, design, and methods for the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial," *The American Journal of Cardiology*, vol. 97, no. 12, supplement 1, pp. 9G–19G, 2006.

[27] American Diabetes Association, "Standards of medical care for patients with diabetes mellitus," *Diabetes Care*, vol. 25, supplement 1, pp. S33–S629, 2002.

[28] S. M. Grundy, J. L. Cleeman, C. N. Merz et al., "Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines," *Circulation*, vol. 110, no. 2, pp. 227–239, 2004.

[29] M. F. Magee and W. L. Isley, "Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial," *The American Journal of Cardiology*, vol. 97, no. 12, pp. 20–30, 2006.

[30] B. J. Turner, C. S. Hollenbeck, M. Weiner, and S. S. K. Tang, "A retrospective cohort study of the potency of lipid-lowering therapy and race-gender differences in LDL cholesterol control," *BMCCardiovascular Disorders*, vol. 11, article 58, 2011.

[31] M. C. Rossi, M. R. Cristofaro, S. Gentile et al., "Sex disparities in the quality of diabetes care: biological and cultural factors may play a different role for different outcomes. A cross-sectional observational study from the amd annals initiative," *Diabetes Care*, vol. 36, no. 10, pp. 3162–3168, 2013.

[32] N. Johnston, K. Schenck-Gustafsson, and B. Lagerqvist, "Are we using cardiovascular medications and coronary angiography appropriately in men and women with chest pain?" *European Heart Journal*, vol. 32, no. 11, pp. 1331–1336, 2011.

[33] R. Bugiardini, A. T. Yan, R. T. Yan et al., "Factors influencing underutilization of evidence-based therapies in women," *European Heart Journal*, vol. 32, no. 11, pp. 1337–1344, 2011.

[34] D. M. Becker, J. Segal, D. Vaidya et al., "Sex differences in platelet reactivity and response to low-dose aspirin therapy," *The Journal of the American Medical Association*, vol. 295, no. 12, pp. 1420–1427, 2006.

[35] J. S. Berger, M. C. Roncaglioni, F. Avanzini, I. Pangrazzi, G. Tognoni, and D. L. Brown, "Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials," *The Journal of the American Medical Association*, vol. 295, no. 3, pp. 306–313, 2006.

[36] M. A. Huser, T. S. Evans, and V. Berger, "Medication adherence trends with statins," *Advances in Therapy*, vol. 22, no. 2, pp. 163–171, 2005.

[37] K. J. Kroba, D. D. Yin, E. Alemao, and E. Steinhagen-Thiessen, "Real-world effectiveness of lipid-lowering therapy in male and female outpatients with coronary heart disease: relation to pre-treatment low-density lipoprotein-cholesterol, pre-treatment coronary heart disease risk, and other factors," *European Journal of Cardiovascular Prevention and Rehabilitation*, vol. 12, no. 1, pp. 37–45, 2005.